Press Releases Year None2024202320222021202020192018201720162015201420132012 April 1, 2024 Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development March 18, 2024 Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium March 13, 2024 RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit March 11, 2024 RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting March 7, 2024 Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update February 29, 2024 Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024 February 13, 2024 Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury February 9, 2024 Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering February 6, 2024 Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering January 16, 2024 RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS
April 1, 2024 Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
March 18, 2024 Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
March 13, 2024 RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
March 11, 2024 RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
March 7, 2024 Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 29, 2024 Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024
February 13, 2024 Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
February 9, 2024 Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering
January 16, 2024 RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS